A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer
Abstract
Single-agent selinexor has limited activity in heavily pretreated patients with metastatic triple-negative breast cancer.Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side-effect profile consistent with previous clinical trials.Future studies of selinexor in this population should focus on combination approaches and a biomarker-driven strategy to identify patients most likely to benefit.This phase II trial evaluated...
Paper Details
Title
A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer
Published Date
Apr 17, 2019
Journal
Volume
24
Issue
7
Pages
887 - e416
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History